雷贝拉唑联合硫糖铝治疗胃溃疡的临床疗效分析

2019-03-27谷群黄坤明

健康大视野 2019年5期

谷群黄坤明

【摘要】目的分析雷贝拉唑联合硫糖铝治疗胃溃疡临床效果。方法选2015年1月～2018年1月淄川区医院胃溃疡患者90例为研究对象，因用药不同分对照组和实验组每组45例。对照组予雷贝拉唑，实验组在此基础上联合硫糖铝，分析2组溃疡愈合率、复发率、药物不良反应率。结果实验组溃疡愈合率91.11%复发率2.22%，与对照组愈合率68.89%和复发率15.56%相比，差异有统计学意义 P<0.05。2组药物不良反应率6.67 % vs 9.52 %对比差异无统计学意义。结论胃溃疡在雷贝拉唑治疗基础上，加硫糖铝治疗方案其效果更好、安全，可临床推广。

【关键词】雷贝拉唑；硫糖铝；胃溃疡；复发

Abstract Objective Analyze the clinical efficacy of Rabeprazole combined with Sucralfate in the treatment of benign gastric ulcer.Method 90 patients with benign gastric ulcer in Zichuan District hospital from January 2015to January 2018 were selected as target group. According to the computer random principle， they were divided into two groups， the control group and the observation group，45cases in each group. The two group received routine treatment in gastroenterology department. The control group was treated with Bella.The observation group was treated with additional sucralfate on the basis of the control group. The total effective rate， recurrence rate and incidence of adverse reactions were compared between the 2 groups.Result After the treatment， for the observation group， the total effective rate of treatment is 91.11%， and the recurrence rate is 2.22%. All indicators have been improved. For the control group， the total effective rate of treatment is 68.89%， and the recurrence rate is 15.56%. The difference was statistically significant（P<0.05） with the comparison between the two group. However， there was no significant difference in the incidence of adverse reactions between the two groups （6.67% vs 9.52%）.Conclusion It is safe and effective that on the basis of Rabeprazole as the main treatment， combined with Sucralfate in the treatment of benign gastric ulcer. And it is worthy of further promotion.

KeyWords Rabeprazole Sucralfate Benign gastric ulcer Recurrence

【中图分类号】R573 【文献标识码】B 【文章编号】1005-0019（2019）05-0-01

胃溃疡是常见的消化科疾病，表现为上腹部有规律有节律的疼痛，伴或不伴出血穿孔。目前其发生率持续上升，且影响人们工作学习及生活1。本次研究为提高治疗效果及改善预后，以雷贝拉唑联合硫糖铝方案治疗胃溃疡取得良好效果，现报道如下。

1 资料与方法

1.1 一般资料选我院胃溃疡患者90例，随机分为对照组和实验组每组45例。对照组男25例女20例；平均年龄66.52±10.22岁；实验组男24例女21例；平均年龄（67.45±10.47）岁；2组一般资料比较差异无统计学意义。

纳入标准：①除外中毒、HP感染、糖尿病等②年龄40～80岁，胃镜/病理诊断胃溃疡。③无其他系统肿瘤。④签署同意书并配合完成。

排除标准：①哺乳期和妊娠期女性②多脏器功能障碍/不全③免疫系统及肿瘤疾病患者④对研究药物过敏

1.2 方法

1.2.1 治疗方法：

对照组雷贝拉唑2：口服20 mg/次/d连续治疗6周。

实验组在对照组基础上+硫糖铝：雷贝拉唑用法同上；硫糖铝口服1包/次2次/d治疗6周。2组患者清淡饮食戒烟戒酒。记录临床表现。治疗结束后1月及6月复查胃镜观察溃疡愈合情况。

1.2.2 观察指标：记录2组治疗后临床疗效（无效、有效、显效、痊愈）、不良反应率及半年复发率。